Alexander & Baldwin to Participate in Nareit's REITweek: 2025 Investor Conference
HONOLULU, May 30, 2025 /PRNewswire/ -- Alexander & Baldwin, Inc. (NYSE: ALEX) ("A&B" or "Company"), a Hawai'i-based owner, operator, and developer of high-quality commercial real estate in Hawai'i, today announced that its management team will participate in Nareit's REITweek: 2025 Investor Conference in New York. A&B will present an overview of its business and operations, followed by a question and answer session.
Alexander & Baldwin PresentationDate: Tuesday, June 3, 2025Time: 9:30 a.m. – 10:00 a.m. Eastern TimeEvent Link: Alexander & Baldwin Webcast
The webcast may be accessed at the above link. A replay of the webcast will also be made available. Investor Materials for the conference scheduled for June 2–5, 2025, may be accessed on the Company's website at www.alexanderbaldwin.com.
About Alexander & Baldwin, Inc.Alexander & Baldwin, Inc. (NYSE: ALEX) (A&B) is the only publicly-traded real estate investment trust to focus exclusively on Hawai'i commercial real estate and is the state's largest owner of grocery-anchored, neighborhood shopping centers. A&B owns, operates and manages approximately 4.0 million square feet of commercial space in Hawai'i, including 21 retail centers, 14 industrial assets and four office properties, as well as 146 acres of ground lease assets. Over its 155-year history, A&B has evolved with the state's economy and played a leadership role in the development of the agricultural, transportation, tourism, construction, residential and commercial real estate industries.
Learn more about A&B at www.alexanderbaldwin.com.
Contact:Jordan Hinojhino@abhi.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/alexander--baldwin-to-participate-in-nareits-reitweek-2025-investor-conference-302469123.html
SOURCE Alexander & Baldwin, Inc.
Errore nel recupero dei dati
Effettua l'accesso per consultare il tuo portafoglio
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
1 Stock to Buy, 1 Stock to Sell This Week: Broadcom, Lululemon
Trump tariffs, U.S. jobs report, and last batch of earnings will be in focus this week. Broadcom's robust earnings outlook, driven by AI and software growth, makes it a standout buy this week. Lululemon's expected weak results and consumer spending concerns signal a sell. Looking for more actionable trade ideas? Subscribe now and save 45% off InvestingPro! Stocks on Wall Street ended lower on Friday, but the major indices notched a weekly gain and the biggest monthly increase since late 2023 as investors shook off trade war fears. The benchmark S&P 500 jumped 1.9% for the week and 6.2% in May. The tech-heavy Nasdaq Composite advanced 2% on the week and 9.6% for all of May, its biggest monthly gain since November 2023. Meanwhile, the Dow Jones Industrial Average rose 1.6% during the week and 3.9% for the month. Source: More volatility could be in store this week as investors continue to assess the outlook for the economy, inflation, interest rates and corporate earnings amid President Donald Trump's trade war. Most important on the calendar will be Friday's U.S. employment report for May, which is forecast to show the economy added 130,000 positions. The unemployment rate is seen holding steady at 4.2%. Ahead of the jobs report, the ISM manufacturing and services PMIs will also be closely watched. That will be accompanied by a heavy slate of Fed speakers, including Chairman Jerome Powell. Traders maintained bets that the U.S. central bank would cut interest rates by 25 basis points in September, as per the Fed Monitor Tool. Source: Elsewhere, on the earnings docket, there are just a handful of corporate results due as the Q1 reporting season draws to a close, including Broadcom (NASDAQ:AVGO), CrowdStrike (NASDAQ:CRWD), Lululemon (NASDAQ:LULU), Dollar Tree (NASDAQ:DLTR), Dollar General (NYSE:DG), Five Below (NASDAQ:FIVE), and Nio (NYSE:NIO). Regardless of which direction the market goes, below I highlight one stock likely to be in demand and another which could see fresh downside. Remember though, my timeframe is just for the week ahead, Monday, June 2 - Friday, June 6. Broadcom, a leading semiconductor and software company with a market cap exceeding $1 trillion, is poised for a breakout week. The primary catalyst is its upcoming earnings report, expected to showcase robust financial performance. The company's fiscal Q2 report is scheduled to come out on Thursday at 4:15PM ET. Market participants expect a sizable swing in AVGO shares following the print, with options markets pricing in a potential $7 move, or roughly 8%, in either direction post-earnings. Source: InvestingPro Analysts expect Broadcom to deliver $1.57 per share, a robust 43% year-over-year increase, on revenue of $14.95 billion, up 20%. With data center investments continuing to accelerate globally and enterprise software spending showing resilience despite economic uncertainties, Broadcom appears well-positioned to deliver another strong quarter that could drive further appreciation in its shares. Analyst sentiment has been notably positive heading into the print. According to InvestingPro data, all 22 of the latest analyst revisions have been to the upside, highlighting confidence in Broadcom's continued expansion. The company's momentum mirrors that of AI leader Nvidia (NASDAQ:NVDA), fueled by its dominance in data center infrastructure. With a history of beating earnings estimates and a forward P/E ratio that remains attractive compared to peers, Broadcom is well-positioned for upside. Positive guidance and potential dividend increases could further boost investor confidence. Source: AVGO stock ended Friday's session at $242.07, near its 52-week high of $251.88. Shares are up just 4% year-to-date in 2025 after delivering a robust 110% total return in 2024. InvestingPro's AI-powered quantitative model rates Broadcom with a 'GREAT' Financial Health Score of 3.05, reflecting strong profit and sales growth, high gross margins (over 76%), and a long-standing record of rising dividends. Be sure to check out InvestingPro to stay in sync with the market trend and what it means for your trading. Subscribe now for 45% off and position your portfolio one step ahead of everyone else! Conversely, Lululemon, a premium athleisure brand, faces a challenging week as it prepares to release earnings that are expected to disappoint. With intensifying competition in the activewear space and a lofty valuation that leaves little margin for error, LULU is vulnerable to a post-earnings sell-off. The yoga wear retailer is scheduled to release its first quarter update after the U.S. market closes on Thursday at 4:05PM ET. According to the options market, traders are pricing in a massive swing of 8.6% in either direction for LULU stock following the print. Source: InvestingPro The market is bracing for weak financials, driven by a slowdown in U.S. consumer spending on discretionary items like yoga gear and sportswear. Analyst sentiment is overwhelmingly bearish with 19 downward revisions and no upward adjustments in the weeks preceding the report. Lululemon is expected to post an annual gain of 1.6% in adjusted earnings per share to $2.58, with revenue projected to increase by 6.8% from the year-ago period to $2.36 billion. Commentary from executives on the health of the U.S. consumer will be closely watched, as any signs of prolonged weakness could rattle investor confidence. Lululemon's forward guidance already disappointed last quarter, and there's a palpable risk that another underwhelming report could prompt further downgrades. The premium athletic apparel retailer, known for its $128 leggings and $68 workout tanks, faces increasing competition from both established athletic brands and fast-fashion retailers offering similar styles at lower price points. Source: The technical picture for Lululemon stock has deteriorated as well, with shares underperforming the broader market and key retail indices year-to-date. LULU stock closed at $316.47 on Friday, well below its 52-week high of $423.32. As per InvestingPro research, recent analyst commentary paints a picture of declining momentum. Morgan Stanley (NYSE:MS) cut its price target, and BNP Paribas (OTC:BNPQY) downgraded to Underperform, warning of shrinking margins and pricing pressures. Be sure to check out InvestingPro to stay in sync with the market trend and what it means for your trading. Whether you're a novice investor or a seasoned trader, leveraging InvestingPro can unlock a world of investment opportunities while minimizing risks amid the challenging market AI: AI-selected stock winners with proven track record. InvestingPro Fair Value: Instantly find out if a stock is underpriced or overvalued. Advanced Stock Screener: Search for the best stocks based on hundreds of selected filters, and criteria. Top Ideas: See what stocks billionaire investors such as Warren Buffett, Michael Burry, and George Soros are buying. At the time of writing, I am long on the S&P 500, and the Nasdaq 100 via the SPDR® S&P 500 ETF (SPY (NYSE:SPY)), and the Invesco QQQ Trust ETF (QQQ). I am also long on the Invesco Top QQQ ETF (QBIG), and Invesco S&P 500 Equal Weight ETF (RSP). I regularly rebalance my portfolio of individual stocks and ETFs based on ongoing risk assessment of both the macroeconomic environment and companies' financials. The views discussed in this article are solely the opinion of the author and should not be taken as investment advice. Follow Jesse Cohen on X/Twitter @JesseCohenInv for more stock market analysis and insight. Related articles 1 Stock to Buy, 1 Stock to Sell This Week: Broadcom, Lululemon These 4 Quantum Stocks Outperformed in May—Is There More Room to Run? Nvidia Rides the AI Supercycle With Another Beat - And Still Looks Underpriced Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Fast-casual stir-fry chain looking to make central Ohio debut in Gahanna
GAHANNA, Ohio (WCMH) – A fast-casual stir-fry chain may open its first central Ohio location near Gahanna. Honeygrow has applied for a permit to renovate 4782 Morse Road, according to Columbus city documents. A spokesperson said the brand is currently in the midst of lease negotiations for the space. The building formerly housed Mod Pizza, which closed last year amid financial troubles for the chain. Honeygrow has three Ohio eateries, located in Canton, Akron and Strongsville. Founded in 2012, the Pennsylvania-based chain has around 40 locations across the northeastern portion of the United States, according to its website. The business serves a variety of Asian-inspired stir fries, featuring noodles, meat, vegetables and sauce. The eatery also serves salads and desserts, such as fruit cups with sweet toppings called 'honeybars' and brownies. Customers have the option to build their own stir fry bowls, honeybars and salads. Honeygrow offers dine-in and take out at its restaurants, along with catering services. The company said it can not share any further information about the potential Gahanna location at this time. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' 'Patients diagnosed with advanced or metastatic renal cell carcinoma often face a median survival in months after exhausting standard therapies,' said Samer A. Srour, MB ChB, MS, Associate Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and lead investigator of the TRAVERSE trial. 'These updated results from a larger cohort of patients with confirmed CD70 positive tumors provide compelling evidence that treatment with ALLO-316 can reduce tumor burden, control disease, and in some cases deliver durable responses. These findings underscore the clinical promise of an allogeneic CAR T to address the significant unmet needs in solid tumors and offer hope to patients who have exhausted other options.' In the Phase 1b expansion cohort, 22 patients whose tumors had progressed on multiple prior therapies were treated with lymphodepletion and 20 were treated with ALLO-316. All patients had tumors resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had ≥2+ prior TKI, and 41% had prior belzutifan. Sixteen of the ALLO-316 treated patients had a high CD70 Tumor Proportion Score (TPS >50%). The Phase 1b expansion cohort evaluated the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) following a standard FC lymphodepletion regimen (fludarabine (30 mg/m2/day) and cyclophosphamide (500 mg/m2/day) for 3 days). The median time from enrollment to the start of therapy was four days. A single dose of ALLO-316 stabilized or reversed disease progression in the majority of patients. In the 16 patients with CD70 TPS ≥50%, the trial demonstrated a Confirmed Overall Response Rate (ORR) of 31% with 44% achieving a minimum of 30% reduction in tumor burden. Of the five confirmed responders, four maintain ongoing responses, with one in sustained remission for over 12 months. The median duration of response (mDOR) has not yet been reached, indicating the potential for long-term disease control. CD70+ patients Phase 1b(N=20) ORR (confirmed CR or PR per RECIST v1.1), n/N (%) 5/20 (25) CD70 TPS ≥50%CD70 TPS <50% 5/16 (31)0/4 (0) RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; TPS, tumor proportion score The safety profile of ALLO-316 was manageable and consistent with lymphodepletion and an active CAR T product. The most frequent Grade ≥3 events were hematologic and there were no treatment-related Grade 5 events. The most common all-grade adverse events were cytokine release syndrome (CRS) (68%; with no grade ≥3), neutropenia (68%), decreased white blood cell count (68%), anemia (59%), and thrombocytopenia (55%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was 18% (with no grade ≥3) and no graft-versus-host disease (GvHD) occurred. Improved recognition of IEC-HS symptoms led to diagnosis in 36% of patients with 2 patients (9%) experiencing a short-term Grade 3 (one) or Grade 4 (one patient) event. Newly implemented diagnostic and management algorithms significantly mitigated IEC-HS, with no associated Grade 5 events. TEAEs ≥20% incidence in Phase 1b, n (%) Phase 1b (N=22a) All Grades Grade ≥3 Neutropenia 15 (68) 15 (68) White blood cell count decreased 15 (68) 15 (68) Anemia 13 (59) 9 (41) Thrombocytopenia 12 (55) 6 (27) Nausea 8 (36) 0 ALT increased 7 (32) 2 (9) Peripheral edema 7 (32) 0 Pyrexia 7 (32) 0 Arthralgia 6 (27) 0 AST increased 6 (27) 2 (9) Fatigue 5 (23) 0 Headache 5 (23) 0 AEs of Special Interest Any Grade Grade ≥3 CRS 15 (68) 0 Infection 10 (45) 8 (36) IEC-HS 8 (36) 2 (9)b ICANS 4 (18) 0 Graft-versus-host disease 0 0 IEC-HS includes the preferred terms immune effector cell-associated HLH-like syndrome and Hemophagocytic lymphohistiocytosis. a Includes 2 patients who received LD but did not receive ALLO-316 b One patient experienced G4 IEC-HS based on GI bleeding with subsequent improvement and 1 patient experienced G3 IEC-HS based on hypotension managed without pressors with subsequent improvement. About ALLO-316 (TRAVERSE)ALLO-316 is an AlloCAR T™ investigational product targeting CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC. In October 2024 the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation based on the potential of ALLO-316 to address the unmet need for patients with advanced or metastatic RCC. The FDA previously granted Fast Track Designation (FTD) to ALLO-316 in March 2023. In April 2024, the Company announced an award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as 'develop,' 'potential,' 'expect,' 'can,' 'enable,' 'showing,' 'generate,' 'may,' 'could,' 'designed to,' 'promise,' 'hope,' 'ongoing,' 'indicating,' 'mitigate,' 'evaluate,' 'pioneer,' 'goal' or 'will,' including alternative forms thereof, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of ALLO-316 to treat patients with advanced or metastatic RCC or to provide meaningful clinical benefit in patients with advanced RCC; the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors and to generate deep and durable remissions; the potential that ALLO-316 can reduce tumor burden, control disease, and deliver durable responses; the design and potential benefits of our Dagger technology; whether the Dagger® technology will become the next-generation allogeneic platform; ALLO-316 and the Dagger technology's ability to enable robust CAR T cell expansion and persistence and tumor infiltration; the potential of ALLO-316 to address the unmet need in solid tumors or offer hope to patients who have exhausted other options; the transformative potential of our AlloCAR T™ in solid tumors; the potential advantages of the RMAT and Fast Track designation; and our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trials; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; RMAT and Fast Track designations may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval and the designations can be revoked if the criteria for eligibility cease to be met; and challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation under the 'Risk Factors' heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc. Allogene's investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T™ program. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
